The Filing Desk

Solesence

SLSN · Nasdaq · Consumer Staples · Financials, fiscal 2016 to 2025

SLSN · Last close · November 19, 2026
$1.48
Value Solesence yourself

Solesence's revenue rose 18.6% to $62 million in fiscal 2025. Its operating margin was 4.2%, up from 3.8% a year earlier. The diluted share count rose 11.6%.

SOLESENCE, INC. Latest fiscal year ended December 31, 2025 10-K filed March 31, 2026 · 0001999371-26-007345 Updated
Revenue
$62M
18.6%
Operating margin
4.2%
0.4 pts
Net income
$3M
155.6%
Free cash flow
—
 
Return on equity
23.1%
2.5 pts
Market cap
$106M
Nov 19 close
P/E
29.6x
On $0.05 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2020 to 2025, earnings per share grew 5.9% a year and net income 22.9% a year, as new shares raised the share count by 89% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments12211
Debt incl. finance leases—1———
Net debt (negative means net cash)—−1———
Net debt to EBITDA—————
Debt to equity—0.2x———
Interest coverage2.2x−5.9x−4.9x3.0x2.5x
Current ratio1.6x1.2x0.9x1.0x1.8x
Quick ratio0.8x0.6x0.4x0.3x0.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Solesence's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4,785 of Solesence shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Dec 24, 2025Whitmore R JanetDirectorBought2,500$1.91$4,785Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−8.2%35.4%—
Altman Z''−12.07−7.10−4.77
Accruals ratio−9.0%−2.3%24.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positiveFailPassFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Solesence side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
SolesenceFY2518.6%4.2%————
FitLife BrandsFY2526.4%12.3%9.1%———Compare
Natural Health TrendsFY25−7.4%−4.5%−15.2%———Compare
MannatechFY25−8.3%−0.4%−4.0%—−4.1x2Compare
Bioharvest SciencesFY2537.0%−16.2%−27.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue11121412173037375262
Revenue growth4.6%15.7%13.8%−11.9%36.9%72.1%26.6%−0.1%40.4%18.6%
Gross profit343369871317
Research and development2222223444
Operating income−1−1−2−323−2−423
Net income−1−1−2−312−3−513
Diluted EPS (US$)−0.04−0.03−0.06−0.080.030.05−0.05−0.100.020.04
Diluted shares (millions)31313437384749506573
Cash flow
Cash from operations−0−1−1−3−22−2−22−9
Capital expenditure000112315—
Free cash flow−0−1−2−4−30−4−3−3—
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation0000001111
Balance sheet at fiscal year end
Cash and short-term investments2211112211
Debt incl. finance leases————2—1———
Total assets5679142834314546
Total liabilities2358112129313532
Shareholders' equity331238501014
Margins and ratios
Gross margin30.1%30.9%23.2%20.9%35.0%29.5%22.4%19.5%24.9%27.5%
Operating margin−11.8%−6.2%−14.2%−22.4%8.7%8.7%−6.0%−11.0%3.8%4.2%
Net margin−11.9%−6.3%−14.7%−24.0%5.8%7.9%−7.0%−13.2%2.1%4.5%
Free cash flow margin−3.4%−9.4%−10.6%−28.1%−17.2%1.5%−12.0%−8.2%−4.9%—
Rule of 40 (growth + FCF margin)1.1%6.3%3.2%−40.0%19.7%73.7%14.6%−8.2%35.4%—
Return on capital——————————
Return on equity−45.4%−26.2%−90.2%−207.7%46.6%45.5%−43.2%−194.8%20.6%23.1%
Return on assets−27.2%−14.2%−32.4%−37.7%8.6%11.1%−8.5%−15.2%2.9%6.1%
Net debt to EBITDA————0.4x—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Solesence's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Solesence.